Human cytomegalovirus (CMV) is a member of the human herpes virus family.1 CMV infection in otherwise healthy individuals is common and usually results in a mild, non-specific illness while congenital CMV (cCMV), which occurs when the virus is passed from mother to unborn baby, can lead to severe morbidity and mortality outcomes.2
Congenital CMV infection occurs when the virus is passed from the mother to her unborn baby.3 The virus circulates in the mother’s blood and can cross through the placenta to infect the developing fetus. This typically occurs when a pregnant woman is infected with CMV for the first time (primary infection), or the virus is reactivated during pregnancy.3
Expectant mothers experiencing primary CMV infection present the highest risk of transmitting CMV to the developing fetus. In pregnant women, primary CMV infection results in congenital infection in 30% to 35% of the fetuses, whereas non-primary infection gives rise to a fetal infection rate of about 1.1% to 1.7%.2
Congenital CMV infection is the most common congenital infection worldwide. An estimated incidence in developed countries ranges from 0.6 to 0.7% of all live births, resulting in approximately 60,000 neonates born every year with congenital CMV infection in the United States and the European Union combined.4
Congenital CMV is also the leading cause of non-genetic childhood hearing loss and a significant cause of neurodevelopmental delays like cognitive deficit and vision impairment. At birth, infected infants can be symptomatic (10% to 15%) or asymptomatic (85% to 90%), and in both subgroups, infants can develop hearing defects.2
Timely diagnosis of congenital CMV is critical for disease management and intervention. Antiviral medications such as valganciclovir and ganciclovir, along with appropriate follow-up care may improve congenital CMV related hearing and developmental outcomes.2 Infants with congenital CMV shed high levels of the virus in their urine and saliva, and direct detection from these samples can provide a definitive diagnosis.
1. Mocarski, E. S. (1993) Cytomegalovirus biology and replication (p 173-226). In B. Roizman, R. J. Whitley, and C. Lopez (Eds.), The Human Herpesviruses. New York, N.Y: Raven Press.
2.Manickal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B., & Gupta, R. K. (2013). The “silent” global burden of congenital cytomegalovirus. Clinical Microbiology Reviews, 26(1), 86-102.
3.Centers for Disease Control and Prevention. (n.d.). Cytomegalovirus (CMV) and congenital CMV infection. Retrieved from https://www.cdc.gov/cmv/congenital-infection.html
4.Marsico, C. & Kimberlin, D. W. (2017). Congenital cytomegalovirus infection: advances and challenges in diagnosis, prevention and treatment. Italian Journal of Pediatrics, 43(1): 38.
Why to choose it
A real-time PCR assay for the in vitro qualitative detection of cytomegalovirus (CMV) from saliva swab and urine specimens from infants less than 21 days of age.
Excellent Clinical Agreement
The Simplexa™ Congenital CMV Direct kit demonstrated high performance with excellent clinical agreement against a composite reference method consisting of PCR/bi-directional sequencing.
SimplexaTM Congenital CMV Direct Clinical Agreement Study
|Sample TypeSample Type||Positive % Agreement||Negative % Agreement|
|Sample TypeSaliva Swab||Positive % Agreement100100% (53/53)
95% CI: 93.2% to 100.0%
|Negative % Agreement100100% (117/117)
95% CI: 96.8% to 100.0%
|Sample TypeUrine||Positive % Agreement100.0% (49/49)
95% CI: 92.7% to 100.0%
|Negative % Agreement97.6% (121/124)
95% CI: 93.1% to 99.2%
Broad Coverage for Your Testing Needs
Our Simplexa™ Congenital CMV Direct assay provides broad coverage. It is validated for both saliva swab and urine specimens from infants less than 21 days of age.
Simplexa™ Congenital CMV Direct Kit
|Code MOL2250||Reactions 24|
Simplexa™ Congenital CMV Positive Control Pack
|Code MOL2260||Reactions 10|